The effect of β-blocker treatment on renin (A) and aldosterone-to-renin ratio (B). حسب Ningning Wang (560944)

الموضوعات:

Complication subgroup analysis of the RAAS system in T2DM patients. حسب Ningning Wang (560944)

الموضوعات:

Flow diagram of patient selection and subgroup classification. حسب Ningning Wang (560944)

الموضوعات:

The values of angiotensin II حسب Ningning Wang (560944)

الموضوعات:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different hypertension subgroups. حسب Ningning Wang (560944)

الموضوعات:

General characterization of T2DM patients and healthy controls. حسب Ningning Wang (560944)

الموضوعات:

Antihypertensive treatment of 151 T2DM patients with hypertension at different subgroups. حسب Ningning Wang (560944)

الموضوعات:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes at different normotension subgroups. حسب Ningning Wang (560944)

الموضوعات:

Spearman correlation matrix analysis of the RAAS system and glucose metabolism indexes in hypertensive (A) and normotensive (B) patients. حسب Ningning Wang (560944)

الموضوعات:

Lymphocytes decreased in mouse pneumonia model. حسب Qi Xu (134661)

Multiple linear regression analysis results. حسب Muxi Chen (9294270)

الموضوعات:

Estimation of the coefficients of a generalised linear model of posttraumatic stress symptomatology. حسب Beatriz Arregui-Gallego (21553735)

الموضوعات:

Linear trends of weekly prescription rates of NVBP varieties. حسب Chenxuan Zhu (22622476)

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…No added benefit of addition of ruxolitinib is observed on the significant improvement in the urine albumin/creatinine ratio and the anti-dsDNA IgG levels induced by UCB-Tregs.…"

Summary of significant treatment × time effect. حسب Wensheng Xiao (16557866)

Table 2_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…"

Table 1_Bibliometric analysis of global research on the clinical applications of aminoglycoside antibiotics: improving efficacy and decreasing risk.docx حسب Tengxiang Zhao (20749475)

"…Future studies should examine the pharmacokinetic and pharmacodynamic targets of AGs and assess the efficacy and safety of administration by inhalation to improve efficacy and decrease risk.</p>…"

Significant condition. حسب Junxia Zhou (14381598)

"…BET and SEM analyses demonstrated that the specific surface area and porosity (most probable pore size) gradually decreased over time. At various ages, mesopores (cumulative pore diameter, median pore diameter) initially increased and then decreased. …"